These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 33960710)
1. Liquid biopsies to distinguish malignant from benign pulmonary nodules. Tao R; Cao W; Zhu F; Nie J; Wang H; Wang L; Liu P; Chen H; Hong B; Zhao D Thorac Cancer; 2021 Jun; 12(11):1647-1655. PubMed ID: 33960710 [TBL] [Abstract][Full Text] [Related]
2. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules. Li X; Zhang Q; Jin X; Cao L World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454 [TBL] [Abstract][Full Text] [Related]
3. Detecting pulmonary malignancy against benign nodules using noninvasive cell-free DNA fragmentomics assay. Xu S; Luo J; Tang W; Bao H; Wang J; Chang S; Zou Z; Fan X; Liu Y; Jiang C; Wu X ESMO Open; 2024 Aug; 9(8):103595. PubMed ID: 39088983 [TBL] [Abstract][Full Text] [Related]
4. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032 [TBL] [Abstract][Full Text] [Related]
6. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397 [TBL] [Abstract][Full Text] [Related]
7. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules. Xing W; Sun H; Yan C; Zhao C; Wang D; Li M; Ma J BMC Cancer; 2021 Mar; 21(1):263. PubMed ID: 33691657 [TBL] [Abstract][Full Text] [Related]
8. CTCs Detection and Whole-exome Sequencing Might Be Used to Differentiate Benign and Malignant Pulmonary Nodules. Xu C; Xu X; Shao W; Sun H; Liu X; Feng H; Zuo X; Gao J; Wang G; Yang X; Gu R; Ge S; Wang S; Gao L; Zhu G Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):449-460. PubMed ID: 37488082 [TBL] [Abstract][Full Text] [Related]
9. Circulating epigenetic biomarkers in lung malignancies: From early diagnosis to therapy. Tomasetti M; Amati M; Neuzil J; Santarelli L Lung Cancer; 2017 May; 107():65-72. PubMed ID: 27312601 [TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333 [TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer. Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233 [TBL] [Abstract][Full Text] [Related]
12. A Noninvasive Multianalytical Approach for Lung Cancer Diagnosis of Patients with Pulmonary Nodules. Liu QX; Zhou D; Han TC; Lu X; Hou B; Li MY; Yang GX; Li QY; Pei ZH; Hong YY; Zhang YX; Chen WZ; Zheng H; He J; Dai JG Adv Sci (Weinh); 2021 Jul; 8(13):2100104. PubMed ID: 34258160 [TBL] [Abstract][Full Text] [Related]
13. [Establishment and Verification of A Novel Predictive Model of Malignancy for Non-solid Pulmonary Nodules]. Xiao F; Yu Q; Zhang Z; Liu D; Liang C Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):26-33. PubMed ID: 30674390 [TBL] [Abstract][Full Text] [Related]
14. Liquid biopsies based on DNA methylation as biomarkers for the detection and prognosis of lung cancer. Li P; Liu S; Du L; Mohseni G; Zhang Y; Wang C Clin Epigenetics; 2022 Sep; 14(1):118. PubMed ID: 36153611 [TBL] [Abstract][Full Text] [Related]
15. Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. Ostrin EJ; Bantis LE; Wilson DO; Patel N; Wang R; Kundnani D; Adams-Haduch J; Dennison JB; Fahrmann JF; Chiu HT; Gazdar A; Feng Z; Yuan JM; Hanash SM J Thorac Oncol; 2021 Feb; 16(2):228-236. PubMed ID: 33137463 [TBL] [Abstract][Full Text] [Related]
16. The potential of liquid biopsies in gastrointestinal cancer. Wu C; Zhang J; Li H; Xu W; Zhang X Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214 [TBL] [Abstract][Full Text] [Related]
18. Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles. Corvigno S; Johnson AM; Wong KK; Cho MS; Afshar-Kharghan V; Menter DG; Sood AK Mol Cancer Ther; 2022 Jul; 21(7):1067-1075. PubMed ID: 35545008 [TBL] [Abstract][Full Text] [Related]
19. Dynamic contrast-enhanced computed tomography for the diagnosis of solitary pulmonary nodules: a systematic review and meta-analysis. Weir-McCall JR; Joyce S; Clegg A; MacKay JW; Baxter G; Dendl LM; Rintoul RC; Qureshi NR; Miles K; Gilbert FJ Eur Radiol; 2020 Jun; 30(6):3310-3323. PubMed ID: 32060716 [TBL] [Abstract][Full Text] [Related]
20. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]